Literature DB >> 20977483

Clearance of maternal isohemagglutinins from infant circulation (CME).

Salima Shaikh1, Steven R Sloan.   

Abstract

BACKGROUND: Non-group O neonates require testing for passively acquired maternal isohemagglutinins for them to receive type-specific red blood cells (RBCs), according to the latest edition of the AABB Standards. A neonate is defined as an infant up to 4 months old in the AABB Standards, and many blood banks tend to stop testing for maternal anti-A and/or anti-B after 4 months of age. In lieu of such testing, group O RBCs are usually transfused to infants up to 4 months of age. This practice can limit the overall supply of group O RBCs available to other patients. STUDY DESIGN AND METHODS: A retrospective study of 1309 infants up to 4 months of age was performed, to assess the age by which passively acquired maternal isohemagglutinins are cleared from infant circulation. Detection of isohemagglutinins was performed by mixing sample sera and observing agglutination, followed by incubation and addition of anti-immunoglobulin anti-human globulin (antiglobulin test phase).
RESULTS: The data show that 6.4% of infants up to 1 month of age had maternal isohemagglutinins, while none of the infants ranging from 2 to 4 months of age had maternal isohemagglutinins in their sera.
CONCLUSIONS: Maternal isohemagglutinins are rare after the first month of life and patients who are at least 2 months old can safely receive ABO type-compatible RBC units without testing for passively acquired maternal anti-A and/or anti-B.
© 2010 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20977483     DOI: 10.1111/j.1537-2995.2010.02912.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  3 in total

1.  Red blood cell transfusion in newborn infants.

Authors:  Robin K Whyte; Ann L Jefferies
Journal:  Paediatr Child Health       Date:  2014-04       Impact factor: 2.253

2.  Comparison of outcomes of group O vs non-group O premature neonates receiving group O RBC transfusions.

Authors:  Leonard I Boral; Zane G Staubach; Reny de Leeuw; Duncan C Macivor; Richard Kryscio; Henrietta S Bada
Journal:  Am J Clin Pathol       Date:  2013-12       Impact factor: 2.493

3.  Anti-A isohaemagglutinin titres and SARS-CoV-2 neutralization: implications for children and convalescent plasma selection.

Authors:  Daniele Focosi
Journal:  Br J Haematol       Date:  2020-07-08       Impact factor: 8.615

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.